
Aptargroup (ATR) Stock Forecast & Price Target
Aptargroup (ATR) Analyst Ratings
Bulls say
AptarGroup has demonstrated strong growth potential, particularly through its AMS Solutions segment, which has been expanding at a compound annual growth rate (CAGR) of approximately 10%, contributing around 5% to total fiscal year 2024 revenue. The company's Injectables business has also exhibited significant growth at a 9% CAGR, supported by an evolving global drug pipeline trending towards biologics and increased demand for GLP-1 therapies. This dual growth in high-value products is anticipated to further enhance AptarGroup's profit margins, solidifying a positive financial outlook for the company.
Bears say
AptarGroup faces significant challenges that could negatively impact its financial performance, particularly in its transition to a majority Pharma segment which may be slower than anticipated, thereby limiting growth and margin expansion. The company's reliance on international markets exposes it to currency fluctuations and economic cycles, which can adversely affect industry demand and revenue stability. Furthermore, risks associated with regulatory inspections, potential facility shutdowns, shipping liabilities, increasing competition, and the protection of proprietary intellectual property further complicate AptarGroup's financial outlook.
This aggregate rating is based on analysts' research of Aptargroup and is not a guaranteed prediction by Public.com or investment advice.
Aptargroup (ATR) Analyst Forecast & Price Prediction
Start investing in Aptargroup (ATR)
Order type
Buy in
Order amount
Est. shares
0 shares